The Clinical Observation of Inflammation Theory for Depression: The Initiative of the Formosa Long COVID Multicenter Study (FOCuS)
暂无分享,去创建一个
J. Chang | K. Su | C. Liang | Che-Sheng Chu | Shao-Cheng Wang | Kai-Jie Yang | S. K. Satyanarayanan | Shu-Tsen Liu | Sheng-Che Lin | Ching-Fang Sun | Chia-Chun Yang | Chia-Chun Yang
[1] K. Su,et al. Unresolved Systemic Inflammation, Long COVID, and the Common Pathomechanisms of Somatic and Psychiatric Comorbidity , 2022, Journal of clinical medicine.
[2] M. S. Johnson,et al. Psychiatric symptoms in COVID-19-positive individuals in the general population: Trajectories of depression, anxiety, and insomnia , 2022, Psychiatry Research.
[3] F. Benedetti,et al. Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue , 2022, Journal of Psychiatric Research.
[4] M. Taquet,et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients , 2022, The Lancet Psychiatry.
[5] A. Al-Harrasi,et al. Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches , 2022, Biomolecules.
[6] K. Bhaskaran,et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records , 2022, Nature Communications.
[7] F. Benedetti,et al. Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment , 2022, CNS Drugs.
[8] Shaghayegh Haghjooy Javanmard,et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021 , 2022, medRxiv.
[9] M. Covasa,et al. Do Diet and Dietary Supplements Mitigate Clinical Outcomes in COVID-19? , 2022, Nutrients.
[10] Long Khanh-Dao Le,et al. Modelling the potential acute and post-acute burden of COVID-19 under the Australian border re-opening plan , 2022, BMC Public Health.
[11] K. Miskowiak,et al. Trajectory of cognitive impairments over 1 year after COVID‐19 hospitalisation: Pattern, severity, and functional implications , 2022, European Neuropsychopharmacology.
[12] C. Pariante,et al. Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19 , 2022, Brain, Behavior, and Immunity.
[13] A. Steptoe,et al. Long-term psychological consequences of long Covid: a propensity score matching analysis comparing trajectories of depression and anxiety symptoms before and after contracting long Covid vs short Covid , 2022, medRxiv.
[14] Z. Bhat,et al. Delving the role of nutritional psychiatry to mitigate the COVID-19 pandemic induced stress, anxiety and depression , 2022, Trends in Food Science & Technology.
[15] Nelson B Rodrigues,et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis , 2021, Brain, Behavior, and Immunity.
[16] B. Carter,et al. Long-term effects of COVID-19 on mental health: A systematic review , 2021, Journal of Affective Disorders.
[17] Janet Diaz,et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.
[18] C. Pariante. Increased Inflammation in Depression: A Little in All, or a Lot in a Few? , 2021, The American journal of psychiatry.
[19] F. Limosin,et al. Do Anxiety and Depression Predict Persistent Physical Symptoms After a Severe COVID-19 Episode? A Prospective Study , 2021, Frontiers in Psychiatry.
[20] A. Toubasi,et al. Meta-analysis of prevalence: the psychological sequelae among COVID-19 survivors , 2021, International journal of psychiatry in clinical practice.
[21] Reed J. D. Sorensen,et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic , 2021, The Lancet.
[22] C. Correll,et al. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A) , 2021, Journal of Affective Disorders.
[23] U. Merle,et al. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] C. Correll,et al. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic , 2021, Journal of Affective Disorders.
[25] P. Brambilla,et al. Neuroinflammation in Major Depressive Disorder: A Review of PET Imaging Studies Examining the 18-kDa Translocator Protein. , 2021, Journal of affective disorders.
[26] Lauren E. Oberlin,et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment , 2021, Current opinion in psychiatry.
[27] T. Penzel,et al. Brain Mechanisms of COVID-19-Sleep Disorders , 2021, International journal of molecular sciences.
[28] E. Vieta,et al. Mind long COVID: Psychiatric sequelae of SARS-CoV-2 infection , 2021, European Neuropsychopharmacology.
[29] M. Maes,et al. A Review of the Global Impact of the COVID-19 Pandemic on Public Mental Health, with a Comparison Between the USA, Australia, and Poland with Taiwan and Thailand , 2021, Medical science monitor : international medical journal of experimental and clinical research.
[30] M. Boldrini,et al. How COVID-19 Affects the Brain. , 2021, JAMA psychiatry.
[31] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.
[32] L. Bairy,et al. LONG TERM COMPLICATIONS OF COVID-19 , 2021, International Journal of Medical and Biomedical Studies.
[33] F. Benedetti,et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up , 2021, Brain, Behavior, and Immunity.
[34] C. Pariante,et al. The three frontlines against COVID-19: Brain, Behavior, and Immunity , 2021, Brain, Behavior, and Immunity.
[35] A. Morice,et al. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? , 2021, Lung.
[36] B. Penninx,et al. Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts , 2021, Molecular Psychiatry.
[37] M. Sojka,et al. SARS-CoV-2 RNA in the Cerebrospinal Fluid of a Patient with Long COVID , 2021, Therapeutic advances in infectious disease.
[38] R. Marioni,et al. Structural brain correlates of serum and epigenetic markers of inflammation in major depressive disorder , 2020, Brain, Behavior, and Immunity.
[39] Paul J. Harrison,et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA , 2020, The Lancet Psychiatry.
[40] M. Ota,et al. Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study , 2021, Frontiers in Pharmacology.
[41] M. Sivan,et al. NICE guideline on long covid , 2020, BMJ.
[42] C. Pariante,et al. Omega-3 fatty acids in the psychological and physiological resilience against COVID-19 , 2020, Prostaglandins, Leukotrienes and Essential Fatty Acids.
[43] S. Hollon,et al. Mental health and clinical psychological science in the time of COVID-19: Challenges, opportunities, and a call to action. , 2020, The American psychologist.
[44] C. Nemeroff,et al. The Bidirectional Relationship of Depression and Inflammation: Double Trouble , 2020, Neuron.
[45] G. Shields,et al. Psychosocial Interventions and Immune System Function: A Systematic Review and Meta-analysis of Randomized Clinical Trials. , 2020, JAMA psychiatry.
[46] Tedros Adhanom Ghebreyesus. Addressing mental health needs: an integral part of COVID‐19 response , 2020, World psychiatry : official journal of the World Psychiatric Association.
[47] Alex Brito,et al. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis , 2020, Nutrients.
[48] Paolo Fusar-Poli,et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.
[49] M. Rotondi,et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system , 2020, Cytokine & Growth Factor Reviews.
[50] Guiqiang Wang,et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality , 2020, International Journal of Antimicrobial Agents.
[51] Sung-Wan Kim,et al. Using psychoneuroimmunity against COVID-19 , 2020, Brain, Behavior, and Immunity.
[52] O. Howes,et al. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls , 2020, Brain, Behavior, and Immunity.
[53] Suxin Wan,et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.
[54] C. Pariante,et al. Is there neuroinflammation in depression? Understanding the link between the brain and the peripheral immune system in depression. , 2020, International review of neurobiology.
[55] M. Maes,et al. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder , 2019, Psychotherapy and Psychosomatics.
[56] F. Giuliani,et al. The Role of Inflammation in Depression and Fatigue , 2019, Front. Immunol..
[57] Peter B. Jones,et al. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels , 2019, Psychological Medicine.
[58] K. Hashimoto,et al. The Efficacy of Omega-3 Fatty Acids for Depressive Symptoms among Pregnant Women in Japan and Taiwan: A Randomized, Double-Blind, Placebo-Controlled Trial (SYNCHRO; NCT01948596) , 2018, Psychotherapy and Psychosomatics.
[59] M. Craske,et al. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation , 2018, Neuroscience & Biobehavioral Reviews.
[60] Y. Matsuoka,et al. Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms , 2018, JAMA network open.
[61] George M. Slavich,et al. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials , 2016, Annals of the New York Academy of Sciences.
[62] M. Irwin,et al. Mind–body therapies and control of inflammatory biology: A descriptive review , 2016, Brain, Behavior, and Immunity.
[63] Andrew H. Miller,et al. The role of inflammation in depression: from evolutionary imperative to modern treatment target , 2015, Nature Reviews Immunology.
[64] Michael R. Irwin,et al. The Effects of Mind-Body Therapies on the Immune System: Meta-Analysis , 2014, PloS one.
[65] M. Irwin,et al. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. , 2014, Psychological bulletin.
[66] Qiu-qin Han,et al. Inflammation: a mechanism of depression? , 2014, Neuroscience Bulletin.
[67] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[68] K. Su,et al. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. , 2007, The Journal of clinical psychiatry.
[69] Shih-Yi Huang,et al. Omega-3 polyunsaturated fatty acids for postpartum depression. , 2004, American journal of obstetrics and gynecology.